Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Increases By 28.0%

KALA BIO, Inc. (NASDAQ:KALA) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 37,500 shares, a growth of 28.0% from the October 15th total of 29,300 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average trading volume of 17,600 shares, the days-to-cover ratio is presently 2.1 days.

Institutional Trading of KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new position in KALA BIO, Inc. (NASDAQ:KALA) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO as of its most recent SEC filing. Institutional investors and hedge funds own 24.61% of the company’s stock.

KALA BIO Stock Performance

NASDAQ KALA opened at $6.70 on Friday. The company’s 50 day simple moving average is $6.02 and its two-hundred day simple moving average is $6.29. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 3.07. KALA BIO has a 1 year low of $4.21 and a 1 year high of $10.97. The stock has a market capitalization of $30.89 million, a PE ratio of -0.54 and a beta of -2.13.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. Analysts predict that KALA BIO will post -11.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on KALA. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of KALA BIO in a report on Friday. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of KALA BIO in a report on Monday, August 19th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.